News Release

Maternal asthma medication associated with premature births, small birth weight in infants

Peer-Reviewed Publication

PLOS

Maternal asthma medication associated with premature births, small birth weight in infants

image: Pregnant women stopping asthma medicines may be at risk of preterm birth. Picture description: Pregnant woman pictured holding pill packet. view more 

Credit: Swansea University distributed under a CC-BY licence

Prescriptions for asthma medicines, whether continued or discontinued during pregnancy, are associated with premature births and small birth weight, according to a new study published this week in the open-access journal PLOS ONE by Sue Jordan of Swansea University and colleagues.

The prevalence of asthma in pregnancy has increased worldwide in recent years and these is no consensus on the effect of asthma or asthma medications on perinatal outcomes. However, it is known that medicines prescribed for asthma can cross the placenta.

In the new study, researchers analyzed all births in Wales after 24 gestational weeks between January 2000 and December 2010, with associated maternal prescription data (117,717 births). Exposure to any asthma medication was defined as the woman having been prescribed at least one asthma medicine in the three trimesters of pregnancy. Pregnancies terminated for fetal anomalies, infants with congenital anomalies, pregnancies that were not singletons, and those exposed to other drugs or substances associated with perinatal outcomes were excluded.

Prescriptions for asthma were associated with birth before 32 weeks gestation (aOR 1.33, 95%CI 1.10-1.61) and birthweights below the 10th percentile (aOR 1.10, 95%CI 1.03-1.18). Moreover, the discontinuation of asthma medicine during pregnancy was associated with both birth before 32 weeks (aOR 1.53, 95%CI 1.11-2.10) and birth before 37 weeks gestation (aOR 1.22, 95%CI 1.06-1.41). Stillbirth was also more prevalent among women prescribed asthma medicines than the unexposed population (aOR 1.56, 95%CI 1.21-2.00), particularly if the medicines had been discontinued during pregnancy (aOR 1.91, 95%CI 1.29-2.82). The authors conclude that increased monitoring, targeted support and active asthma management are needed before, during and after pregnancy.

The authors add: "This analysis of prescription records for over 100,000 pregnancies found that women who stopped their asthma medicines during pregnancy were at increased risk of preterm birth and not breastfeeding at 6-8 weeks, whereas women who continued with their inhaled corticosteroids were at lower risk. Prescriptions records could be used to identify the women who need extra help and support."

###

Press-only preview: https://plos.io/3ob0dzQ

Contact: Sue Jordan, s.e.jordan@swansea.ac.uk, Ph.: +44 1639830836; Swansea University Press Office, press@swansea.ac.uk, Ph.: 01792 295050

Image Caption: Pregnant women stopping asthma medicines may be at risk of preterm birth. Picture description: Pregnant woman pictured holding pill packet.

Image Credit: Swansea University distributed under a CC-BY licence

Citation: Davies G, Jordan S, Thayer D, Tucker D, Humphreys I (2020) Medicines prescribed for asthma, discontinuation and perinatal outcomes, including breastfeeding: A population cohort analysis. PLoS ONE 15(12): e0242489. https://doi.org/10.1371/journal.pone.0242489

Funding: Funding This paper was developed from the EUROmediCAT project, and uses the cohort identified in that project. The analyses presented here were completed outside the funded period. Financial support for the EUROmediCAT study was provided by the European Union under the 7th Framework Program [grant agreement HEALTH-F5-2011-260598]. Start date: 1 March 2011. Duration: 48 months. Coordinator: Prof. Helen Dolk, University of Ulster. Further information can be found at http://www.euromedicat.eu. The paper is based on data in the all-Wales SAIL databank, which is supported by UK Research and Innovation funding to Swansea University through an Administrative Data Research Centre grant (2018-2021), project reference: ES/S007393/1, Principal Investigator: Professor David Ford. The funder played no part in the study or production of the paper.

Competing Interests: The authors have declared that no competing interests exist.

In your coverage please use this URL to provide access to the freely available article in PLOS ONE: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242489


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.